Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Maravai Lifesciences Holdings (MRVI) Cost of Revenue (2020 - 2025)

Maravai Lifesciences Holdings has reported Cost of Revenue over the past 6 years, most recently at $37.0 million for Q4 2025.

  • Quarterly results put Cost of Revenue at $37.0 million for Q4 2025, changed 0.39% from a year ago — trailing twelve months through Dec 2025 was $151.8 million (up 0.58% YoY), and the annual figure for FY2025 was $151.8 million, up 0.58%.
  • Cost of Revenue for Q4 2025 was $37.0 million at Maravai Lifesciences Holdings, up from $36.0 million in the prior quarter.
  • Over the last five years, Cost of Revenue for MRVI hit a ceiling of $53.3 million in Q4 2022 and a floor of $31.4 million in Q1 2021.
  • Median Cost of Revenue over the past 5 years was $37.7 million (2021), compared with a mean of $38.0 million.
  • Biggest five-year swings in Cost of Revenue: skyrocketed 105.21% in 2021 and later plummeted 34.07% in 2023.
  • Maravai Lifesciences Holdings' Cost of Revenue stood at $39.1 million in 2021, then soared by 36.06% to $53.3 million in 2022, then crashed by 34.07% to $35.1 million in 2023, then increased by 5.87% to $37.2 million in 2024, then decreased by 0.39% to $37.0 million in 2025.
  • The last three reported values for Cost of Revenue were $37.0 million (Q4 2025), $36.0 million (Q3 2025), and $39.6 million (Q2 2025) per Business Quant data.